SCHEMBL16201452

SCHEMBL16201452

CCCN(C)Cc1c[nH]nc1-c1ccc(Oc2ccccc2)c(C(=O)N(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
MOK Q9UQ07 1/20 0.38
LMNA P02545 1/20 0.38
SCN9A Q15858 6/20 0.36
HRH3 Q9Y5N1 1/20 0.36
ALDH1A1 P00352 3/20 0.35
SLC6A2 P23975 2/20 0.35
SLC6A4 P31645 2/20 0.35
PKM P14618 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
MGLL Q99685 1/20 0.34
KDM4E B2RXH2 3/20 0.34
NPSR1 Q6W5P4 2/20 0.34
L3MBTL1 Q9Y468 2/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
LPAR1 Q92633 1/20 0.33
LPAR5 Q9H1C0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201293 0.93 SCN9A (0.37) MAPTLMNASCN9AHRH3ALDH1A1
SCHEMBL16204206 0.91 MOK (0.40) MAPTMOKLMNASCN9AHRH3
SCHEMBL16201454 0.89 MOK (0.38) MAPTMOKLMNASCN9AALDH1A1
SCHEMBL16201451 0.84 ERBB2 (0.47) MAPTMOKSCN9AALDH1A1SLC6A2
SCHEMBL16201441 0.82 ERBB2 (0.40) MOKLMNASCN9AALDH1A1SLC6A2
SCHEMBL16201294 0.81 RIPK1 (0.36) MAPTSCN9AALDH1A1SLC6A2SLC6A4
SCHEMBL16204207 0.81 MOK (0.40) MAPTMOKSCN9AALDH1A1SLC6A2
SCHEMBL16201436 0.81 ALDH1A1 (0.42) MAPTMOKLMNAALDH1A1TSHR
SCHEMBL16201341 0.76 MOK (0.37) MOKALDH1A1KMT2A
SCHEMBL16201292 0.76 ERBB2 (0.47) MAPTSCN9AALDH1A1KDM4ENPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 MAPT 1449/4885MOK 1964/4885LMNA 3763/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 MAPT 1526/4885MOK 2043/4885LMNA 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.